Close

IsoRay (ISR) Enters Class Action Stipulation of Settlement

Go back to IsoRay (ISR) Enters Class Action Stipulation of Settlement

IsoRay, Inc. Enters Into Agreement to Settle Class Action Shareholder Litigation

September 27, 2016 6:00 AM EDT

RICHLAND, Wash., Sept. 27, 2016 ­/PRNewswire/ -- IsoRay, Inc. ("IsoRay") (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck, and gynecological cancers, today announced that on September 23, 2016, it entered into a Stipulation of Settlement (the "Settlement"), pursuant to which IsoRay and IsoRay's former CEO (together, the "Defendants") have, subject to certain conditions and approvals, agreed to settle the previously-disclosed consolidated securities class action litigation, In re IsoRay, Inc. Securities Litigation, Case No.... More